Figure 2.
Clonal evolution under pirtobrutinib treatment. (A) Oncoprint of cleared and acquired mutations (C481S, P = 5.8 × 10-6; T474I, P = 6.4 × 10-5; L528W, P = .001, P value derived from the paired t test) (B) Bar plots showing the distribution of acquired mutations and cleared mutations by genes and by BTK residues, each color represents a gene. (C) VAF at baseline and at progression (PD) for 120 BTK mutations detected at baseline and/or PD. For Figure 3C, the high-sensitivity assay (LoD, 0.5% VAF) was used at baseline.

Clonal evolution under pirtobrutinib treatment. (A) Oncoprint of cleared and acquired mutations (C481S, P = 5.8 × 10-6; T474I, P = 6.4 × 10-5; L528W, P = .001, P value derived from the paired t test) (B) Bar plots showing the distribution of acquired mutations and cleared mutations by genes and by BTK residues, each color represents a gene. (C) VAF at baseline and at progression (PD) for 120 BTK mutations detected at baseline and/or PD. For Figure 3C, the high-sensitivity assay (LoD, 0.5% VAF) was used at baseline.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal